BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 16493048)

  • 1. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.
    Zhang T; Somasundaram R; Berencsi K; Caputo L; Rani P; Guerry D; Furth E; Rollins BJ; Putt M; Gimotty P; Swoboda R; Herlyn M; Herlyn D
    J Immunol; 2005 May; 174(9):5856-63. PubMed ID: 15843590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
    Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
    Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
    Huang H; Xiang J
    Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
    Mendt M; Cardier JE
    Melanoma Res; 2017 Aug; 27(4):300-308. PubMed ID: 28445180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin.
    Cardones AR; Murakami T; Hwang ST
    Cancer Res; 2003 Oct; 63(20):6751-7. PubMed ID: 14583470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
    Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
    Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.
    Murakami T; Maki W; Cardones AR; Fang H; Tun Kyi A; Nestle FO; Hwang ST
    Cancer Res; 2002 Dec; 62(24):7328-34. PubMed ID: 12499276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.
    Zhang T; Somasundaram R; Berking C; Caputo L; Van Belle P; Elder D; Czerniecki B; Hotz S; Schuchter L; Spitz FR; Berencsi K; Rani P; Marincola F; Qiu R; Herlyn D
    Cancer Biol Ther; 2006 Oct; 5(10):1304-12. PubMed ID: 16929176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
    Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
    J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
    Sorrentino C; Miele L; Porta A; Pinto A; Morello S
    Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.
    Ieranò C; D'Alterio C; Giarra S; Napolitano M; Rea G; Portella L; Santagata A; Trotta AM; Barbieri A; Campani V; Luciano A; Arra C; Anniciello AM; Botti G; Mayol L; De Rosa G; Pacelli R; Scala S
    Cell Death Dis; 2019 Jul; 10(8):562. PubMed ID: 31332163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12.
    Inngjerdingen M; Rolstad B; Ryan JC
    J Immunol; 2003 Sep; 171(6):2889-95. PubMed ID: 12960311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
    Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
    J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
    Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
    J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent.
    Papeta N; Chen T; Vianello F; Gererty L; Malik A; Mok YT; Tharp WG; Bagley J; Zhao G; Stevceva L; Yoon V; Sykes M; Sachs D; Iacomini J; Poznansky MC
    Transplantation; 2007 Jan; 83(2):174-83. PubMed ID: 17264814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.